Literature DB >> 25881713

Antibody-mediated neutralization of perfringolysin o for intracellular protein delivery.

Nicole J Yang1,2, David V Liu1,2, Demetra Sklaviadis3, Dan Y Gui4,2, Matthew G Vander Heiden4,5,2, K Dane Wittrup1,3,2.   

Abstract

Perfringolysin O (PFO) is a member of the cholesterol-dependent cytolysin (CDC) family of bacterial pore-forming proteins, which are highly efficient in delivering exogenous proteins to the cytoplasm. However, the indiscriminate and potent cytotoxicity of PFO limits its practical use as an intracellular delivery system. In this study, we describe the design and engineering of a bispecific, neutralizing antibody against PFO, which targets reversibly attenuated PFO to endocytic compartments via receptor-mediated internalization. This PFO-based system efficiently mediated the endosomal release of a co-targeted gelonin construct with high specificity and minimal toxicity in vitro. Consequently, the therapeutic window of PFO was improved by more than 5 orders of magnitude. Our results demonstrating that the activity of pore-forming proteins can be controlled by antibody-mediated neutralization present a novel strategy for utilizing these potent membrane-lytic agents as a safe and effective intracellular delivery vehicle.

Entities:  

Keywords:  cholesterol-dependent cytolysin; endosomal release; intracellular delivery; neutralizing antibody; perfringolysin O; protein delivery

Mesh:

Substances:

Year:  2015        PMID: 25881713      PMCID: PMC4876977          DOI: 10.1021/mp500797n

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  44 in total

1.  Epidermal growth factor receptor downregulation by small heterodimeric binding proteins.

Authors:  Benjamin J Hackel; Jason R Neil; Forest M White; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2011-12-09       Impact factor: 1.650

2.  Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling.

Authors:  Benjamin J Hackel; Atul Kapila; K Dane Wittrup
Journal:  J Mol Biol       Date:  2008-06-24       Impact factor: 5.469

Review 3.  FN3: a new protein scaffold reaches the clinic.

Authors:  Laird Bloom; Valerie Calabro
Journal:  Drug Discov Today       Date:  2009-07-02       Impact factor: 7.851

4.  Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes.

Authors:  K D Lee; Y K Oh; D A Portnoy; J A Swanson
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

5.  A vector-free microfluidic platform for intracellular delivery.

Authors:  Armon Sharei; Janet Zoldan; Andrea Adamo; Woo Young Sim; Nahyun Cho; Emily Jackson; Shirley Mao; Sabine Schneider; Min-Joon Han; Abigail Lytton-Jean; Pamela A Basto; Siddharth Jhunjhunwala; Jungmin Lee; Daniel A Heller; Jeon Woong Kang; George C Hartoularos; Kwang-Soo Kim; Daniel G Anderson; Robert Langer; Klavs F Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

6.  Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.

Authors:  Jamie B Spangler; Mandana T Manzari; Elizabeth K Rosalia; Tiffany F Chen; K Dane Wittrup
Journal:  J Mol Biol       Date:  2012-06-15       Impact factor: 5.469

7.  Introduction of antisense oligonucleotides into cells by permeabilization with streptolysin O.

Authors:  E L Barry; F A Gesek; P A Friedman
Journal:  Biotechniques       Date:  1993-12       Impact factor: 1.993

8.  Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin.

Authors:  Chester J Provoda; Ethan M Stier; Kyung-Dall Lee
Journal:  J Biol Chem       Date:  2003-06-27       Impact factor: 5.157

9.  Production and characterization of neutralizing and nonneutralizing monoclonal antibodies against listeriolysin O.

Authors:  F Nato; K Reich; S Lhopital; S Rouyre; C Geoffroy; J C Mazie; P Cossart
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.

Authors:  Ritsuko Sawada-Hirai; Ivy Jiang; Fei Wang; Shu Man Sun; Rebecca Nedellec; Paul Ruther; Alejandro Alvarez; Diane Millis; Phillip R Morrow; Angray S Kang
Journal:  J Immune Based Ther Vaccines       Date:  2004-05-12
View more
  3 in total

1.  Proteome-Scale Screening to Identify High-Expression Signal Peptides with Minimal N-Terminus Biases via Yeast Display.

Authors:  Patrick V Holec; Karen V Camacho; Kathryn C Breuckman; Jody Mou; Michael E Birnbaum
Journal:  ACS Synth Biol       Date:  2022-06-10       Impact factor: 5.249

2.  Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins.

Authors:  Nicole J Yang; Monique J Kauke; Fangdi Sun; Lucy F Yang; Katie F Maass; Michael W Traxlmayr; Yao Yu; Yingda Xu; Robert S Langer; Daniel G Anderson; K Dane Wittrup
Journal:  Nucleic Acids Res       Date:  2017-07-27       Impact factor: 16.971

Review 3.  Inhibition of Pore-Forming Proteins.

Authors:  Neža Omersa; Marjetka Podobnik; Gregor Anderluh
Journal:  Toxins (Basel)       Date:  2019-09-19       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.